71478-56-3

Basic information

• Product Name: 8-BROMO-2,6-DIMETHYL-3H-QUINAZOLIN-4-ONE
• Synonyms: 8-BROMO-2,6-DIMETHYL-3H-QUINAZOLIN-4-ONE;8-broMo-2-Methyl-4H-benzo[d][1,3]oxazin-4-one
• CAS NO: 71478-56-3
• Molecular Formula: C10H9BrN2O
• Molecular Weight: 253.09526
• Mol File: 71478-56-3.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 8-BROMO-2,6-DIMETHYL-3H-QUINAZOLIN-4-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 8-BROMO-2,6-DIMETHYL-3H-QUINAZOLIN-4-ONE(71478-56-3)
• EPA Substance Registry System: 8-BROMO-2,6-DIMETHYL-3H-QUINAZOLIN-4-ONE(71478-56-3)

Safety Data

• Hazardous Substances Data: 71478-56-3(Hazardous Substances Data)

Upstream product

• 101080-38-0 N-(2-bromophenyl)-2-isonitrosoacetanilide 
• 615-36-1 2-bromoaniline 
• 104670-74-8 methyl 2-amino-3-bromobenzoate 
• 20780-74-9 7-bromoisatin 
• 20776-51-6 2-amino-3-bromo benzoic acid 
• 108-24-7 acetic anhydride 

Downstream Products

• 221298-75-5 2-methyl-4-chloro-8-bromo-quinazoline 
• 1268520-96-2 C₁₀H₉N₃O₂ 
• 1263413-81-5 8-bromo-2,3-dimethyl-3H-quinazolin-4-one 

Relevant articles and documents

Discovery and development of extreme selective inhibitors of the ITD and D835Y mutant FLT3 kinases

Aberrant activation of FMS-like tyrosine receptor kinase 3 (FLT3) is implicated in the pathogenesis of acute myeloid leukemia (AML) in 20–30% of patients. In this study we identified a highly selective (phenylethenyl)quinazoline compound family as novel potent inhibitors of the FLT3-ITD and FLT3-D835Y kinases. Their prominent effects were confirmed by biochemical and cellular proliferation assays followed by mice xenograft studies. Our modelling experiments and the chemical structures of the compounds predict the possibility of covalent inhibition. The most effective compounds triggered apoptosis in FLT3-ITD AML cells but had either weak or no effect in FLT3-independent leukemic and non-leukemic cell lines. Our results strongly suggest that our compounds may become therapeutics in relapsing and refractory AML disease harboring various ITD and tyrosine kinase domain mutations, by their ability to overcome drug resistance.

Quinazolines with intra-molecular hydrogen bonding scaffold (iMHBS) as PI3K/mTOR dual inhibitors

Intra-molecular hydrogen bonding was introduced to the quinazoline motif to form a pseudo ring (intra-molecular H-bond scaffold, iMHBS) to mimic our previous published core structures, pyrido[2.3-D]pyrimidin-7-one and pteridinone, as PI3K/mTOR dual inhibitors. This design results in potent PI3K/mTOR dual inhibitors and the purposed intra-molecular hydrogen bonding structure is well supported by co-crystal structure in PI3Kγ enzyme. In addition, a novel synthetic route was developed for these analogs.

Search for non-steroidal anti-inflammatory agents. Part 1: Synthesis of 2-alkyl/aryl-3-benzimidazolylalkylquinazolon-4(3H)-ones.

Sixteen title compounds have been synthesized and some of them have shown interesting results in antiinflammatory screening against carrageenin-induced inflammation. In addition, the compounds were found to be central nervous system depressants and relatively non-toxic.